Citi raised the firm’s price target on Roivant Sciences (ROIV) to $35 from $26 and keeps a Buy rating on the shares. The firm views the company’s Phase 2 data for brepocitinib in cutaneous sarcoidosis as “encouraging.” It added revenue for the indication into the model.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ROIV:
- Roivant Sciences price target raised to $33 from $26 at H.C. Wainwright
- Roivant Sciences Earnings Call Highlights Brepocitinib Surge
- Roivant Sciences price target raised to $26 from $22 at BofA
- Roivant Sciences price target raised to $30 from $24 at Jefferies
- Roivant Sciences price target raised to $30 from $28 at Guggenheim